Modern view on the role of Toll-like receptors in the pathogenesis of rheumatoid arthritis and atherosclerosis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review summarizes information indicating the generality of the pathogenetic links of rheumatoid arthritis and atherosclerosis, as well as participation in their development of such components of the immune system as Toll-like receptors, with description of structure and functions. The results of recent studies on the role of Toll-like receptors 5 in the development and progression of rheumatoid arthritis and atherosclerosis are discussed.

全文:

受限制的访问

作者简介

David Bestaev

North Ossetian State Medical Academy

Email: davidbestaev@rambler.ru
MD, Head of the Department of Internal Diseases № 3

S. Ktsoeva

North Ossetian State Medical Academy

Z. Brtsieva

North Ossetian State Medical Academy

L. Khutieva

North Ossetian State Medical Academy

L. Osipova

North Ossetian State Medical Academy

N. Burduli

North Ossetian State Medical Academy

O. Kotsoeva

North Ossetian State Medical Academy

T. Bestaeva

NOSMA Clinical Hospital

Rheumatology Department

参考

  1. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В. кн. Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой М., 2008. С. 290-331.
  2. Мазуров В.И. и др. Ревматоидный артрит(клиника, диагностика, лечение). СПб., 2000.
  3. Turesson C., Jacobsson L.T., Matteson E.L. Cardiovascular co-morbidity in rheumatic diseases. Vasc. Health Risk Manag. 2008;4:605-14.
  4. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of Rheumatoid arthritis. Arthr. Rheum. 1994;37:481-94.
  5. Удачкина Е.В., Новикова Д.С., Попкова Т.В., Насонов Е.Л. Роль интерлейкина-6 в развитии атеросклероза при ревматоидном артрите. Современная ревматология. 2013;7(3):25-32.
  6. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthr. Res. Ther. 2011;13(Suppl. 1):5. Doi: http://dx.doi. org/10.1186/1478-6354-13-S1-S5.
  7. Klarenbeek N.B.,Güler-Yüksel M.,vander Heijde D.M., et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann. Rheum. Dis. 2010;69(12):2107-13. Doi: http://dx.doi. org/10.1136/ard.2010.131201.
  8. Rommel C., Camps M., Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007;7(3):191-201. Doi: http://dx.doi. org/10.1038/nri2036.
  9. Jorgensen K.T., Wiik A., Pedersen M., et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann. Rheum. Dis. 2008;67(6):860-66. Doi: http://dx. doi.org/10.1136/ard.2007.073825.
  10. Deane K.D., O'Donnell C.I., Hueber W., et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthr. Rheum. 2010;62(11):3161-72. Doi: http:// dx. doi.org/10.1002/art.27638.
  11. Kokkonen H., Soderstrom I., Rocklov J., et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthr. Rheum. 2010;62(2):383-91. Doi: http://dx.doi. org/10.1002/art.27186.
  12. van de Sande M.G., de Hair M.J., van der Leij C., et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann. Rheum. Dis. 2011;70(5):772-77. Doi: http:// dx.doi.org/10.1136/ard.2010.139527.
  13. John H., Kitas G., Toms T., Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2009;23(1):71-82. Doi: http://dx. doi.org/10.1016/j.berh.2008.11.007.
  14. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 2008;121(10 Suppl. 1):21-31. Doi: http://dx.doi. org/10.1016/j.amjmed.2008.06.014.
  15. Тертов В.В., Качарова В.Г., Садаян Х.С. Холестеринсодержащие циркулирующие иммунные комплексы - компонент сыворотки крови у больных ишемической болезнью сердца. Кардиология. 1989;8:35-8.
  16. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: basic mechanism oxidation, inflammation, and genetic. Circulation. 1995;91(9):2488-96.
  17. Климов А.Н. Иммунореактивность и атеросклероз. Л., 1986. С. 6-11.
  18. Хаитов P.M., Пинегин Б.В. Современные подходы к оценке основных этапов фагоцитарного процесса. Иммунология. 1995;3:1-13.
  19. Коган A.X. Фагоцитозависимые кислородные свободно-радикальные механизмы аутоагрессии в патогенезе внутренних болезней. Вестник РАМН. 1999;2:3-10.
  20. Honda H.M., Lietinger N., Frankel M., et al. Induction of monocyte hinging to endothelial cells by MM-LDL. Role of lipoxygenase metabolites. Arterioscler. Thromb. Vasc. Biol. 1999;19(3):680-86.
  21. Титов В.Н. Аполипопротеин (а) - маркер активности атеросклеротического процесса. Терапевтический архив. 1993;12:79-82.
  22. Sattar N., McCarey D.W., Capell H., et al. Explaining how «how-grade» systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957-63. Doi: http://dx.doi. org/10.1161/01.CIR.0000099844.31524.05.
  23. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthr. Rheum. 2007;57(1):125-32. Doi: http://dx.doi.org/10.1002/art.2248.
  24. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999;340(2):115-26. Doi: http://dx. doi.org/10.1056/NEJM199901143400207.
  25. Ozbalkan Z., Efe C., Cesur M., et al. Новые данные о связи ревматоидного артрита и атеросклероза. Атеросклероз и дислипидемии. 2011;3(4):4.
  26. Лебедев К.А., Понякина И.Д. Иммунология образраспознающих рецепторов (интегральная иммунология). М., 2009. 256 с.
  27. Симбирцев А.С. Толл-белки: специфические рецепторы неспецифического иммунитета. Иммунология. 2005;6:368-77.
  28. Хаитов Р.М., Пащенков М.В., Пинегин Б.В. Роль паттерн-распознающих рецепторов во врожденном и адаптивном иммунитете. Иммунология. 2009;1:66-76.
  29. Ковальчук Л.В., Ганковская Л.В., Мешкова Р.Я. Клиническая иммунология и аллергология с основами общей иммунологии. М., 2011. 234 с.
  30. Ярилин А.А. Иммунология. М., 2010. 562 с.
  31. Medzhitov R., Janeway C. Innate immuniry. N. Engl. J. Med. 2000;343(5):338-44. Doi: http://dx. doi. org/10.1056/NEJM200008033430506.
  32. Janeway C.A. Approaching asymptome? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989;54(Pt. 1):1-13. Doi:http:// dx.doi.org/10.1101/SQB.1989.054.01.003.
  33. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001;1(2):135-45. Doi: http:// dx. doi.org/10.1038/35100529.
  34. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity Immunol. Rev. 2009;227(1):221-33. Doi: http:// dx.doi.org/10.1111/j.1600-065X.2008.00731.x.
  35. Тухватуллин А.И., Логунов Д.Ю., Щербинин Д.Н. Toll-подобные рецепторы и их адапторные молекулы. Биохимия. 2010;75(9):1224-43
  36. McGettrick A.F., O'Neill L.A. Localization and trafficking of Toll-like receptors: an important mode of regulation. Curr. Opin. Immunol. 2010;22(1):20 7. Doi: http://dx.doi.org/10.1016/j.coi.2009. 12.002
  37. Sabroe R.F., Read R.C., Whyte M.K., et al. Toll-like receptors in health and disease: complex questions remain. J. Immunol. 2003;171(4):1630-35.
  38. Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005;17(1):1-14. Doi: http://dx.doi.org/10.1093/intimm/dxh186.
  39. Engel A.L., Holt G.E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert. Rev. Clin. Pharmacol. 2011;4(2):275-89. Doi: http://dx.doi. org/10.1586/ecp.11.5.
  40. Liu Y., Chen H., Sun Y., Chen F. Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection. Mol. Biol. Rep. 2012;39(2):1163 72. Doi: http://dx.doi.org/10.1007/s11033-011-0846-7
  41. Yonkers N.L., Rodriguez B., Asaad R., et al. Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells. PLoS. One. 2011;6(9):23884. http://dx.doi.org/10.1371/ journal.pone.0023884.
  42. Wolska A., Lech-Maranda E., Robak T. Toll-like receptors and their role in hematologic malignancies. Curr. Mol. Med. 2009;9(3):324-35.
  43. Huang L.Y., Dumontelle J.L., Zolodz M., et al. Use of toll-like receptor assays to detect and identify microbial contaminants in biological products. J. Clin. Microbiol. 2009;47(11):3427-34. Doi: http://dx. doi.org/10.1128/JCM.00373-09.
  44. Mashima R., Saeki K., Yoshimura A., et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling. J. Biol. Chem. 2005;280(50):41289-97. Doi: http:// dx.doi.org/10.1074/jbc.M508221200.
  45. Jain S., Chodisetti S.B., Agrewala J.N., et al. CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B. cells. PloS. One. 2011;6:20651. Doi: http://dx. org/10.1371/ journal.pone.0020651.
  46. Salem M.L., El-Naggar S.A., Cole D.J. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell. Immunol. 2010;261(2):134 43. Doi: http://dx.doi.org/10.1016/j. cellimm.2009.11.011
  47. Asprodites N., Zheng L., Geng D., et al. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008;22(10):3628-37. Doi: http://dx. doi.org/10.1096/fj.08-108274.
  48. Pasare C., Medzhitov R. Toll-dependent control mechanisms of CD4 T. cell activation. Immunity. 2004;21(5):733-41. Doi: http://dx.doi. org/10.1016/j.immuni.2004.10.006.
  49. Lin Q., Li M., Fang D., et al. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. Int. Immunopharmacol. 2011;11(10):1422-32. Doi: http://dx.doi. org/10.1016/j.intimp.2011.04.026.
  50. Pasare C., Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. 2003;15(6):677-82. http://dx.doi. org/10.1016/j.coi.2003.09.002.
  51. Macedo L., Pinhal-Enfield G., Alshits V., et al. Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. Am. J. Pathol. 2007;171(6):1774-88. Doi: http://dx.doi. org/10.2353/ajpath.2007.061048.
  52. Макаров О.В., Ковальчук Л.В., Ганковская Л.В. и др. Невынашивание беременности, инфекция, врожденный иммунитет. М., 2007. 196 с.
  53. Толстопятова М.А., Буслаева Г.А., Козлов И.Г. Роль рецепторов врожденного иммунитета в развитии инфекционной патологии у новорожденных детей. Педиатрия. 2009;1:115-20.
  54. Iwahashi M., Yamamura M., Aita T., et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthr. Rheum. 2004;50(5):1457-67. Doi: http://dx.doi.org/10.1002/art.20219.
  55. Radstake T.R., Roelofs M.F., Jenniskens Y.M. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthr. Rheum. 2004;50(12):3856-65. Doi: http://dx.doi. org/10.1002/art.20678.
  56. Sorensen L.K., Havemose-Poulsen A., Sonder S.U., et al. Blood cell gene expression profiling in subjects with aggressive periodontitis and chronic arthritis. J. Periodontol. 2009;80(2):28-9. Doi: http:// dx.doi.org/10.1902/jop.2009.080347.
  57. Huang Q., Ma Y., Adebayo A., Pope R.M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthr. Rheum. 2007;56(7):2192-201. Doi: http://dx.doi. org/10.1002/art.22707.
  58. Huang Q.Q., Pope R.M. The role of toll-like receptors in rheumatoid arthritis. Curr. Rheumatol. Rep. 2009;11(5):357-64.
  59. Cole J.E., Georgiou E., Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm. 2010;2010:393946. Doi: http://dx.doi.org/10.1155/2010/393946.
  60. Muzio M., Bosisio D., Polentarutti N., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR in dendritic cells. J. Immunol. 2000;164(11): 5998-6004.
  61. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002;168(9):4531-37.
  62. Bjorkbacka H., Kunjathoor V.V., Moore K.J., et al. Reduced atherosclerosis in myd88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 2004;10(4):416-21. Doi: http://dx.doi. org/10.1038/nm1008.
  63. Mullick A.E., Soldau K., Kiosses W.B., et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J. Exp. Med. 2008;205(2):373-83. Doi: http://dx. doi.org/10.1084/jem.20071096.
  64. Kim S.-J. Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis. J. Immunol. 2014;193(8):3902-13. Doi: http://dx. doi.org/10.4049/jimmunol.1302998.
  65. Means T.K., Hayashi F., Smith K.D., et al. The Tolllike receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. 2003;170(10):5165-75.
  66. Chamberlain N.D., Vila O.M., Volin M.V., et al. TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels. J. Immunol. 2012;189(1):475-83. Doi: http://dx. doi.org/10.4049/jimmunol.1102977.
  67. Марусенко И.М. Терапия ревматоидного артрита с применением генно-инженерных биологических препаратов в Республике Карелия. Современная ревматология. 2013;4:97-100.
  68. Алексеева Е.И., Алексеева А.М., Базарова Т. М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006;2(5):2-30.
  69. Лукина Г.В., Сигидин Я.А., Позднякова Е.С. и др. Инфликсимаб в российской клинической практике. Современная ревматология. 2012;3:37-43.
  70. O'Gradaigh D., Ireland D., Bord S., et al. Joint erosion in RA: interaction between tumor necrosis factor alfa, interleukin 1 and receptor activator of nuclear factor kB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 2004;63(4):354-59.
  71. Komai N., Morita Y., Sakuta T., et al. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. 2007;17(5):385-90. Doi: http://dx.doi.org/10.1007/s10165-007-0605-8.
  72. Nishida S., Okada Y., Nawata M., et al. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody Endocr. J. 2008;55(1):213-16.
  73. Popa C., van den Hoogen F.H., Radstake T.R. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2007;66(11):1503-7. Doi: http://dx.doi. org/10.1136/ard.2006.066191.
  74. Dahlqvist S.R., Engstrand S., Berglin E., Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during longterm infliximab therapy Scand. J. Rheumatol. 2006;35(2):107-11. Doi: http://dx.doi. org/10.1080/03009740500474578.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##